Gilead Sciences, Inc. (NASDAQ:GILD) Stake Reduced by Measured Wealth Private Client Group LLC

Measured Wealth Private Client Group LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 2,313 shares of the biopharmaceutical company’s stock after selling 137 shares during the quarter. Measured Wealth Private Client Group LLC’s holdings in Gilead Sciences were worth $214,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of GILD. nVerses Capital LLC acquired a new stake in Gilead Sciences in the 3rd quarter valued at approximately $25,000. HHM Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares in the last quarter. Valued Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares during the period. YANKCOM Partnership bought a new stake in shares of Gilead Sciences during the fourth quarter valued at about $28,000. Finally, Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences in the fourth quarter worth about $29,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $96.04 on Friday. The company has a market capitalization of $119.69 billion, a price-to-earnings ratio of 1,067.11, a P/E/G ratio of 1.37 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $100.51. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The stock’s fifty day simple moving average is $92.97 and its 200-day simple moving average is $86.49.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.29 EPS. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 4.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on GILD shares. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Mizuho raised their price objective on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Sanford C. Bernstein assumed coverage on Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target on the stock. Finally, Piper Sandler upped their price objective on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $98.39.

Insider Activity at Gilead Sciences

In other news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. The trade was a 67.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares in the company, valued at $12,886,126.44. This represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 572,824 shares of company stock valued at $53,611,715. Corporate insiders own 0.29% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.